Join STAT reporter Andrew Joseph for an online chat about the country’s first FDA-approved medication made from marijuana. He’ll take your questions about the future of marijuana regulation by states and the FDA, the potential rescheduling of cannabis and its components, and what makes the newly approved drug different from older medications that have components similar to those of marijuana.
To read our chat archive, scroll down just a bit and you’ll see the conversation.
Regarding the issue of pricing – doing a little math helps anchor the debate. GW Pharma’s trial showed you need A LOT of CBD to decrease seizure frequency.
Typical 12-year old = 40 kg
GW Pharma recommended dose = 10 mg / kg / day = 400 mg / day (this is 40x the amount of a typical THC dose [10mg])
400 mg / day * 365 days / year = 146,000 mgs / year
Typical CBD pricing from a dispensary = $0.12 / mg
Total cost if you went to a dispensary instead of GW = $17,520 per year
So, if GW Pharma goes with a pricing of $25,000 per year, their markup is relatively close to that of a typical dispensory. I’m sure their production costs are higher than the typical grow operations since it’s regulated by the FDA. I found the math surprising and it made the $25,000 – $50,000 per year number often quoted as a target price seem not as outragous.
A possible way to push the DEA would be a citizens lawsuit accusing the states of allowing easy access to minors of cannabis and cannabis product because of weak state laws, not hard to imagine in the present business environment.
Comments are closed.